Stronghold Plus

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

selamectin, sarolaner

Available from:

Zoetis Belgium SA

ATC code:

QP54AA55

INN (International Name):

selamectin, sarolaner

Therapeutic group:

mačke

Therapeutic area:

Противопаразитарные sredstva, insekticidi i repelenti макроциклических лактонов , kombinacije

Therapeutic indications:

Za mačke sa ili prijeti rizikom od mješovitih parazitskih infestacija krpeljima i buhama, ušima, grčevima, gastrointestinalnim nematodama ili heartwormu. Veterinarsko medicinsko sredstvo iskazuje se isključivo kada se u istom trenutku upućuje na uporabu protiv krpelja i jednog ili više drugih ciljnih parazita.

Product summary:

Revision: 4

Authorization status:

odobren

Authorization date:

2017-02-08

Patient Information leaflet

                                18
B. UPUTA O VMP
19
UPUTA O VMP ZA
STRONGHOLD PLUS 15 MG/2,5 MG OTOPINA ZA NAKAPAVANJE NA KOŽU ZA MAČKE
≤2,5 KG
STRONGHOLD PLUS 30 MG/5 MG OTOPINA ZA NAKAPAVANJE NA KOŽU ZA MAČKE
>2,5–5 KG
STRONGHOLD PLUS 60 MG/10 MG OTOPINA ZA NAKAPAVANJE NA KOŽU ZA MAČKE
>5–10 KG
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
SERIJE U PROMET, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za
puštanje serije u promet:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIJA
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Stronghold Plus 15 mg/2,5 mg otopina za nakapavanje na kožu za mačke
≤2,5 kg
Stronghold Plus 30 mg/5 mg otopina za nakapavanje na kožu za mačke
>2,5–5 kg
Stronghold Plus 60 mg/10 mg otopina za nakapavanje na kožu za mačke
>5–10 kg
selamektin/sarolaner
3.
NAVOĐENJE DJELATNE(IH) TVARI I DRUGIH SASTOJAKA
Svaka jedinična doza (pipeta) sadržava:
DJELATNE TVARI:
Stronghold Plus otopina za
nakapavanje
Ukupni volumen
jedinične doze
(ml)
selamektin (mg)
sarolaner (mg)
Mačke ≤2,5 kg
0,25
15
2,5
Mačke >2,5–5 kg
0,5
30
5
Mačke >5–10 kg
1
60
10
POMOĆNE TVARI:
0,2 mg/ml butilhidroksitoluen
Otopina za nakapavanje.
Bistra, bezbojna do žuta otopina.
4.
INDIKACIJA(E)
Za mačke koje su infestirane ili su pod rizikom od miješanih
parazitskih infestacija krpeljima, buhama,
ušima, grinjama, gastrointestinalnim nematodima ili srčanim crvima.
Ovaj veterinarsko-medicinski
proizvod indiciran je isključivo kada je istovremeno indicirana
upotreba protiv krpelja te jednog ili
više drugih ciljnih parazita.
EKTOPARAZITI
-
Za tretiranje i prevenciju infestacija buhama (
_Ctenocephalides_
spp.). Ovaj veterinarsko-
medicinski proizvod neposredno i trajno ubija buhe i djeluje protiv
novih infestacija tijekom 5
tjedana. Proizvod ubija odrasle buhe prije nego što polože jaja u
periodu od 5 tjedana. Svojim
20
ovicidnim i larvicidnim djelovanjem ovaj veterinarsko-medicinski
proizvod mo
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Stronghold Plus 15 mg/2,5 mg otopina za nakapavanje na kožu za mačke
≤2,5 kg
Stronghold Plus 30 mg/5 mg otopina za nakapavanje na kožu za mačke
>2,5–5 kg
Stronghold Plus 60 mg/10 mg otopina za nakapavanje na kožu za mačke
>5–10 kg
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Svaka jedinična doza (pipeta) sadrži:
DJELATNE TVARI:
Stronghold Plus otopina za
nakapavanje
Sadržaj pipete
(ml)
selamektin (mg)
sarolaner (mg)
Mačke ≤2,5 kg
0,25
15
2,5
Mačke >2,5–5 kg
0,5
30
5
Mačke >5–10 kg
1
60
10
POMOĆNE TVARI:
0,2 mg/ml butilhidroksitoluen.
Potpuni popis pomoćnih tvari vidjeti u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Otopina za nakapavanje.
Bistra, bezbojna do žuta otopina.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Mačke.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Za mačke koje su infestirane ili su pod rizikom od miješanih
parazitskih infestacija krpeljima, buhama,
ušima, grinjama, gastrointestinalnim nematodima ili srčanim crvima.
Ovaj veterinarsko-medicinski
proizvod indiciran je isključivo kada je istovremeno indicirana
upotreba protiv krpelja te jednog ili
više drugih ciljnih parazita.
EKTOPARAZITI:
-
Za tretiranje i prevenciju infestacija buhama (
_Ctenocephalides_
spp.). Ovaj veterinarsko-
medicinski proizvod neposredno i trajno ubija buhe i djeluje protiv
novih infestacija tijekom 5
tjedana. Proizvod ubija odrasle buhe prije nego izlegu jajašca
tijekom 5 tjedana. Svojim
ovicidnim i larvicidnim djelovanjem ovaj veterinarsko-medicinski
proizvod može pomoći u
suzbijanju postojećih infestacija buhama iz okoliša, na području
dostupnom životinji.
-
Proizvod se može upotrebljavati kao dio strategije liječenja
alergijskog dermatitisa uzrokovanog
buhama (FAD).
-
Tretiranje infestacija krpeljima. Ovaj veterinarsko-medicinski
proizvod ima neposredan i trajan
akaricidni učinak tijekom 5 tjedana na
_Ixodes ricinus _
i
_Ixodes hexagonus_
, a 4 tjedna na
_Dermacentor reticulatus _
i

                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 20-12-2021
Public Assessment Report Public Assessment Report Bulgarian 09-03-2017
Patient Information leaflet Patient Information leaflet Spanish 20-12-2021
Public Assessment Report Public Assessment Report Spanish 09-03-2017
Patient Information leaflet Patient Information leaflet Czech 20-12-2021
Public Assessment Report Public Assessment Report Czech 09-03-2017
Patient Information leaflet Patient Information leaflet Danish 20-12-2021
Public Assessment Report Public Assessment Report Danish 09-03-2017
Patient Information leaflet Patient Information leaflet German 20-12-2021
Public Assessment Report Public Assessment Report German 09-03-2017
Patient Information leaflet Patient Information leaflet Estonian 20-12-2021
Public Assessment Report Public Assessment Report Estonian 09-03-2017
Patient Information leaflet Patient Information leaflet Greek 20-12-2021
Public Assessment Report Public Assessment Report Greek 09-03-2017
Patient Information leaflet Patient Information leaflet English 20-12-2021
Public Assessment Report Public Assessment Report English 09-03-2017
Patient Information leaflet Patient Information leaflet French 20-12-2021
Public Assessment Report Public Assessment Report French 09-03-2017
Patient Information leaflet Patient Information leaflet Italian 20-12-2021
Public Assessment Report Public Assessment Report Italian 09-03-2017
Patient Information leaflet Patient Information leaflet Latvian 20-12-2021
Public Assessment Report Public Assessment Report Latvian 09-03-2017
Patient Information leaflet Patient Information leaflet Lithuanian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 20-12-2021
Public Assessment Report Public Assessment Report Lithuanian 09-03-2017
Patient Information leaflet Patient Information leaflet Hungarian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 20-12-2021
Public Assessment Report Public Assessment Report Hungarian 09-03-2017
Patient Information leaflet Patient Information leaflet Maltese 20-12-2021
Public Assessment Report Public Assessment Report Maltese 09-03-2017
Patient Information leaflet Patient Information leaflet Dutch 20-12-2021
Public Assessment Report Public Assessment Report Dutch 09-03-2017
Patient Information leaflet Patient Information leaflet Polish 20-12-2021
Public Assessment Report Public Assessment Report Polish 09-03-2017
Patient Information leaflet Patient Information leaflet Portuguese 20-12-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 20-12-2021
Public Assessment Report Public Assessment Report Portuguese 09-03-2017
Patient Information leaflet Patient Information leaflet Romanian 20-12-2021
Public Assessment Report Public Assessment Report Romanian 09-03-2017
Patient Information leaflet Patient Information leaflet Slovak 20-12-2021
Public Assessment Report Public Assessment Report Slovak 09-03-2017
Patient Information leaflet Patient Information leaflet Slovenian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 20-12-2021
Public Assessment Report Public Assessment Report Slovenian 09-03-2017
Patient Information leaflet Patient Information leaflet Finnish 20-12-2021
Public Assessment Report Public Assessment Report Finnish 09-03-2017
Patient Information leaflet Patient Information leaflet Swedish 20-12-2021
Public Assessment Report Public Assessment Report Swedish 09-03-2017
Patient Information leaflet Patient Information leaflet Norwegian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 20-12-2021
Patient Information leaflet Patient Information leaflet Icelandic 20-12-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 20-12-2021

Search alerts related to this product